(Reuters) - Amgen, the word's largest biotechnology company by sales, on Monday said it would buy privately held Ilypsa, which is developing a drug for chronic kidney disease, for $420 million.
Amgen said the Alantos acquisition has been approved by the boards of both companies and Alantos shareholders. It expects the deal to close in the third quarter.
Read more at Reuters.com Mergers News
Amgen said the Alantos acquisition has been approved by the boards of both companies and Alantos shareholders. It expects the deal to close in the third quarter.
Read more at Reuters.com Mergers News
No comments:
Post a Comment